Hemispherian Raises EUR10M in Financing


Hemispherian, an Oslo, Norway-based preclinical pharmaceutical corporate, raised €10m in financing.

The financing incorporated:

  • €2.5M in grant investment
  • €7.5M in fairness financing from the Eu Innovation Council (EIC) Accelerator fund.

The corporate intends to make use of the price range to advance GLIX1, one in every of lead belongings, thru a section I and section II scientific trial.

Led by way of Adam Robertson, PhD, CSO, and Zeno Albisser, CEO, Leader Medical Officer, Hemispherian is a pharmaceutical corporate desirous about growing a small molecule medication (GLIX). GLIX compounds goal the TET2 enzyme and turn on the DNA injury reaction leading to most cancers cellular dying. The corporate’s compound, GLIX1, is in late-stage preclinical construction for the remedy of glioblastoma, a dangerous most cancers of the central frightened device and the main explanation for dying by way of illness in youngsters.



Leave a Comment